ECHELON-2研究——本妥昔单抗将外周T细胞淋巴瘤的治疗效果提升至新高度。 - Suppr

ECHELON-2 - brentuximab raises PTCL outcomes to new levels.

作者信息

Killock David

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2019 Mar;16(3):145. doi: 10.1038/s41571-018-0163-3.

DOI:10.1038/s41571-018-0163-3

PMID:30602757

Abstract

摘要

相似文献

ECHELON-2 - brentuximab raises PTCL outcomes to new levels.

Nat Rev Clin Oncol. 2019 Mar;16(3):145. doi: 10.1038/s41571-018-0163-3.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.

Br J Haematol. 2013 Jul;162(1):138-41. doi: 10.1111/bjh.12326. Epub 2013 Apr 17.

The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.

Future Oncol. 2022 Feb;18(4):519-535. doi: 10.2217/fon-2021-1032. Epub 2021 Dec 1.

Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.

Am J Manag Care. 2020 Feb 1;26(2):e41-e49. doi: 10.37765/ajmc.2020.42400.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16.

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.

Oncologist. 2023 Jun 2;28(6):520-530. doi: 10.1093/oncolo/oyad068.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.

引用本文的文献

Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.

MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug.

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.

Sci Rep. 2019 Dec 30;9(1):20302. doi: 10.1038/s41598-019-56891-0.

本文引用的文献

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

ECHELON-2 - brentuximab raises PTCL outcomes to new levels.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献